Business
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
PALO ALTO, Calif., January 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1806,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/f7a46d60d6c718bb30c7dc7a83d906b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U4SVW2i1a3qDa6q096xJbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f7a46d60d6c718bb30c7dc7a83d906b1","width":960,"height":329},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5G7WoBtOkb8kj6smDeXs_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f7a46d60d6c718bb30c7dc7a83d906b1","width":1200,"height":411}},"lazy":false},{"type":"text","content":"Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif., January 19, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.","length":357,"tagName":"p"},{"type":"text","content":"Under the multi-year collaboration agreement, Guardant and Merck aim to:","length":72,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Use Guardant’s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck’s global clinical studies,","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Evaluate opportunities to develop novel therapies using Guardant liquid biopsy tests as a companion diagnostic, and","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Partner for global commercialization of drugs and companion diagnostics including in US, Asia-Pacific, UK and EU markets.","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":""This strategic collaboration allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today," said Helmy Elt...